Bhageria Industries Q4 FY26: A Chemical Reaction of Record Sales and Regulatory Gas Leaks

The dye is cast, and for Bhageria Industries Ltd (BIL), the colors are looking surprisingly bright on the top line, even if the air near their Tarapur plant recently got a bit… spicy. We are looking at a company that has managed to pump out record-breaking quarterly sales of ₹271 crore, representing a massive 48.2% YoY growth.

But in the world of specialty chemicals, where there is smoke, there is usually an Oleum leak and a Maharashtra Pollution Control Board (MPCB) closure notice. While the management is busy “sweating assets” at 95-97% utilization, the regulators are busy handing out “voluntary” vacation notices to their sulphonation units. It’s a classic tale of industrial ambition meeting environmental reality.

1. At a Glance – The Volatile Mix of Solar and Acid

Bhageria Industries is not your average one-trick pony. It’s a hybrid beast—part chemical manufacturer, part solar utility, and a tiny, aspiring part pharmaceutical player. They’ve spent the last few years trying to prove that you can manufacture H-Acid and Vinyl Sulphone while simultaneously soaking up the sun in Maharashtra and Chennai.

The Quantitative Hook:

• Revenue Growth: A staggering 47% TTM jump.
• Operating Margin: Sitting at a lean 10.4%, down from historical highs but recovering from the “China dumping” era.
• Debt-to-Equity: A pristine 0.17, proving that while their chemicals might be reactive, their balance sheet is decidedly inert.

The company is currently navigating a treacherous path. On one hand, they are expanding into Plasticizers and Ethoxylates to escape the commodity trap of dye intermediates. On the other, they are dealing with a ₹1.05 crore GST demand and a legal battle with SEBI that’s currently adjourned at the SAT.

The investment thesis here is simple: can the new high-margin verticals (Pharma and Specialty Chemicals) scale up before the core business faces another regulatory shutdown or a raw material price spike? With a Stock P/E of 16.4 against an Industry PE of 18.8, the market is cautiously optimistic, but the “Rating Watch with Negative Implications” from CARE Ratings suggests the credit analysts aren’t ready to join the party just yet.

2. Introduction – The Alchemist’s Ledger

Bhageria Industries (BIL) started its journey in 1989, and like any good chemical company, it has spent decades perfecting the art of turning base raw materials into colorful dye intermediates. However, the modern BIL is trying to undergo a molecular transformation.

They are moving from being a pure-play commodity chemical house to a diversified specialty chemicals platform. This involves moving downstream into Plasticizers (the stuff that makes your PVC cables and footwear flexible) and looking at the lucrative but high-entry-barrier Pharma API market (specifically Vitamin B12 and Corticosteroids).

The company operates out of strategic hubs like Vapi and Tarapur, with a heavy backward integration play into Sulphuric Acid. They don’t just use the acid; they make 300 Tons Per Day (TPD) of it, consuming what they need and offloading the rest to the market. It’s a smart way to control your destiny in a volatile market.

But it’s not all test tubes and lab coats. Bhageria has a massive crush on Solar Power. With over 38 MW of capacity and long-term PPAs with the likes of SECI at fixed tariffs, they have a steady stream of cash flow that acts as a stabilizer when the chemical cycle decides to go into a tailspin.

3. Business Model – WTF Do They Even Do?

If you want to understand Bhageria, think of them as the people who make sure your clothes are blue, your shoes are flexible, and your electricity is green.

The Chemical Hustle:

They are one of the big boys in Dyes Intermediates, specifically H-Acid (4,800 MTPA) and Vinyl Sulphone (3,600 MTPA). These chemicals are the backbone of the textile industry. If people are wearing clothes, Bhageria has a market. They’ve recently added J-Acid and Tobias Acid to the mix to keep things fresh.

The Solar Side-Quest:

While most chemical companies are worried about their carbon footprint, Bhageria decided to just buy the sun. They have a 30MW plant in Ahmednagar and several other installations. This isn’t just for PR; it generates roughly ₹27-30 crore in high-margin revenue annually. It’s the “sleep-well-at-night” portion of the business.

The Pharma Pipe-Dream:

They are investing ₹30-35 crore into an API plant to manufacture Methylcobalamin (Vitamin B12) and Dexamethasone. This is the high-stakes table. They aren’t just making the drugs; they are trying to get US FDA and European CEP approvals to sell to the “regulatory markets” where the real money is.

Wait, so they make acid, solar power, and vitamins? Is this a company or a survivalist’s garage?

4. Financials Overview – The Growth Spurt

Let’s look at the numbers. Bhageria is currently in a massive expansion phase, and the revenue numbers are reflecting that ambition.

Quarterly Performance Comparison (Consolidated)

Management Walk the Talk Analysis:

In the October 2025 concall, management was pounding the table about 95-97% utilization and “volume-driven” growth. Looking at the ₹271 Cr sales figure for March 2026, they clearly delivered on the volume. However, the PAT margin has taken a hit.

Why? Because the management admitted that raw material inflation—specifically the price of acids—has been eating their lunch. They promised a 2-3% margin uplift as export mix improves. While revenue is at an all-time high, the bottom line is still waiting for that “uplift” to fully materialize.

Have you ever seen a company grow sales by 48% and see profits drop? Welcome to the wonderful world of commodity chemical margins.

5. Valuation Discussion – Fair Value Range

Calculating the value of a company that is part-utility (Solar), part-commodity (Dyes), and part-biotech (Pharma) is like trying to price a pizza that also has a car battery on it.

Method 1: P/E Multiple

• Annualised EPS: ₹10.84 (Based on Q4 FY26)
• Median Industry P/E: 18.8x
• Conservative P/E for Dyes: 14x
• Valuation Range: ₹151 to ₹203

Method 2: EV/EBITDA

• TTM EBITDA: ₹91 Cr
• Target Multiple: 10x (Higher due to Solar cash flows)
• Enterprise Value: ₹910 Cr
• Less Debt, Add Cash: ~₹850 Cr Market Cap
• Implied Price: ₹195

Method 3: Discounted Cash Flow (DCF)

Assuming a 10% FCF growth for the next 5 years (driven by Pharma and Plasticizers) and a 12% Discount Rate.

• Base FCF: Using 3-year average adjusted for